MedTrace Logo

Daclizumab Experience in Pediatric Heart Transplant

NCT00486057 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2011-11-21

No results posted yet for this study

Summary

The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation. Literature suggests that the time to first rejection episode can be avoided or delayed by using induction therapy.

Conditions

  • Congenital Disorders

Sponsors & Collaborators

  • Children's Healthcare of Atlanta

    lead OTHER

Principal Investigators

  • Kirk R Kanter, MD · Children's Healthcare of Atlanta, Pediatric Surgery

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486057 on ClinicalTrials.gov